Stanford computer model shows bypass surgery more cost-effective than stents

October 02, 2003

STANFORD, Calif. - Stanford University Medical Center researchers have developed a computer model showing that bypass surgery is more cost-effective in the long run than stents in patients with two or more blocked coronary arteries. Not only does surgery ultimately cost less but it results in a better quality of life, including less chest pain. The results hold even when comparing surgery to newer stents coated with drugs to keep vessels from re-narrowing.

"Stents are hugely popular but also expensive. It's not really clear that the benefit is there for all the patients who receive them," said Cynthia Yock, research associate in the Center for Primary Care and Outcomes Research and lead author of the study that appears in the October edition of the American Journal of Medicine. While it requires less hospitalization time and initially costs less than surgery to install a stent, the savings are lost over roughly five years as these patients suffer greater recurrent chest pain and undergo repeat procedures more often than surgery patients.

To compare these two common artery-clearing treatments, researchers took advantage of previous data from the Bypass Angioplasty Revascularization Investigation, or BARI, conducted from 1988 to 1991. That study compared more than 1,800 patients with two or more coronary arteries blocked who were randomly assigned bypass surgery or angioplasty, a procedure that uses tiny balloons to open blocked arteries. In patients tracked over more than a 10-year period, the study found no significant differences between the two groups other than angioplasty patients requiring repeat procedures more often than surgery patients.

Stents, which help hold blood vessels open after angioplasty, were just becoming available after patients in the BARI trial had received their initial treatments. Since then, the hardware has rapidly taken over; more than three-quarters of angioplasty procedures now include stents. "The technology advances so quickly, especially in cardiology," said Yock. "By the time they finished the follow-up to the BARI trial, one big objection was that it was already obsolete."

So Yock came up with a way to modernize the BARI trial with an elaborate computer model. Along with Mark Hlatky, MD, professor of health research and policy, they incorporated all the known information and expanded it to make estimates about what the costs and quality of life would be had a new technology, such as stents, existed then.

As the model's first test, it had to accurately replicate the results that were seen in the BARI trial. The researchers found that the model did indeed mimic the costs and quality-of-life measures seen in the trial. Once the model was shown to work, they could change parameters based on how much a new procedure costs, what complications it prevents and how it improves patient outcome. "The model allowed us to update the usefulness of the BARI trial for new technology and also to extend the data that we have for the trial, which was just 10 years long, through the lifetime of the patients."

Even the researchers were surprised by their findings. "We expected stenting to be much better than bypass surgery," said Yock. But, she explained, surgery also has had technological advancements, becoming safer and more effective, especially in older and sicker patients, without experiencing the same cost escalation as stenting.

Stents treat only the small section of the artery that has a blockage, while bypass surgery replaces a more extensive length of artery and therefore better protects against disease progression. "Stents are not the curative procedure that people think. If people choose stent procedures they should be prepared to come back," she said. "If your house has a major plumbing problem do you fix one drain, or replace the pipes?"

Surgery also provides better relief from chest pain. "People tend to think that less invasive is better and that new technology has to be better," said Yock. "There has been so much industry hype for stenting but very little industry promotion of surgery, so patients get an imbalanced perspective from the media about therapeutic options available to them. I don't think people realize they can have 15 years of symptom-free life with bypass surgery."

One of the biggest problems with stents is that the blockage often reappears, a process called restenosis, requiring a repeat procedure. A new generation of stents includes drugs to combat the re-narrowing of the blood vessel. While the current study did not address drug-coated stents directly, Yock said their model shows that even eliminating the costs and detrimental effects of restenosis does not make stenting a better choice than bypass surgery for patients with blockages in more than one artery. "My hope is that physicians will say, 'Stents aren't the only good thing for my patient. There are other options that may result in better outcomes'," said Yock.

Stanford collaborators were Derek Boothroyd, PhD, staff statistician; Douglas Owens, MD, at the VA Palo Alto Health Care System and associate professor of medicine at the Center for Primary Care and Outcomes Research; and Alan Garber MD, PhD, also with the VA and professor of medicine at the Center for Primary Care and Outcomes Research.
-end-
The study was funded by grants from the Robert Wood Johnson Foundation and the National Heart Lung and Blood Institute.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

PRINT MEDIA CONTACT: Mitzi Baker at 650-725-2106 (mitzibaker@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at 650-723-6912 (mamalone@stanford.edu)

Stanford University Medical Center

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.